Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

Abstract: The present invention provides a decoy peptide or polypeptide capable of inhibiting the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1), and a pharmaceutical composition, containing the decoy peptide or polypeptide as an active ingredient, for preventing or treating cancer or an angiogenic disease. Furthermore, the present invention provides a method for screening a material for preventing or treating cancer or an angiogenic disease. According to the present invention, it is worth noting that the decoy peptide or polypeptide of the present invention induces apoptosis through the inhibition of the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1); reduces migration and adhesion of endothelial cells; significantly reduces vascular induction, survival, and growth.